

# March 21, 2017

Robert Cybulski, PhD

Marisa D'Angeli, MD

Zahra Escobar, PharmD

Natalia Martinez-Paz, MA, MPA

Paul Pottinger, MD

Laura Quilter, MD

Yuan Zhou, MD

## Agenda

- Didactic: *Empiric Antibiotic Regimens*
- Follow-Up: *PPI Guidance*
- Case Discussion: *Challenges of IDU and OPAT*

URL: <http://rwpoll.com>

Code: uwecho

# Empiric Antibiotics: *Beyond Our Best Guess*

Paul Pottinger, MD, FIDSA  
Associate Professor  
UW Medical Center &  
The University of Washington School of Medicine

March 21, 2017

URL: <http://rwpoll.com>  
Code: uwecho



## Disclosures

- No financial conflicts of interest
- Everything we discuss is QI, thus protected from legal discovery under WA State Code



Paul Pottinger MD



**UWTASP**  
tele-antimicrobial stewardship program

**echo**

## **Empiric Abx: *Starting on the Right Foot***



### Diagnostic uncertainty

Proper syndrome? What bugs are most likely? Or most *dangerous*?

### Integrating resistance data?

What does micro look like *here*?

### Resistance to change

Passion for “sticking with the course”... regardless of testing or clinical outcome!



## **Empiric Abx: *Decision Support***

### **Order Sets**

#### **Benefits...**

1. Behavior control
2. Quality control
3. Path of least resistance

#### **Drawbacks...**

1. Fits most
2. May be cumbersome
3. Only works if used



## Empiric Abx: CAP

### Pearls:

#### **\*\*Vancomycin Dosing:**

Loading dose IV x1 (2 gm if  $\geq 70$  kg, 1.5 gm if  $< 70$  kg), then 15 mg/kg IV q8-12 hours

### Pitfall:

#### **SIGNIFICANT PENICILLIN ALLERGY**

- Example: anaphylaxis, airway compromise, etc.
- CONSULT ALLERGY for evaluation and possible skin testing



## PNEUMONIA

### A. Community-acquired pneumonia [non-aspiration risk] (*S. pneumoniae*, atypicals)

*Diagnosis: Send sputum gram stain & culture, CXR, urinary pneumococcal antigen and blood cultures.*

- Ceftriaxone 1 gm IV q24h **PLUS**
- Azithromycin 500 mg PO/IV q24h x 5 days
- If previous MRSA colonization or infection, **CONSIDER ADDING: Vancomycin\*\***

*Typical Duration: 7 days*

### B. CAP with cavitory lesion(s) (*Oral anaerobes and MRSA*)

- Ampicillin/Sulbactam 3 gm IV q6h **PLUS**
- Azithromycin 500 mg PO/IV q24h **PLUS**
- Vancomycin\*\*

*Typical Duration: 10-21 days*



**CF or Lung transplant patients: Call Pulmonary Transplant and Transplant Infectious Diseases Consult.**

For CAP: Replace Ceftriaxone or Ampicillin-Sulbactam with Moxifloxacin 400mg PO/IV q24h

## Empiric Abx: *HCAP*

### Pearls:

#### F. For all Pneumonia pts:

- ⇒ Anaerobic coverage such as Piperacillin-tazobactam is NOT recommended for HAP or VAP.
- ⇒ During flu seasons, send Flu testing and then give oseltamivir 75mg - 150mg PO/NGT q12.
- ⇒ Yeast in the sputum rarely represents true infection.

### Pitfall:

#### SIGNIFICANT PENICILLIN ALLERGY

- Example: anaphylaxis, airway compromise, etc.
- CONSULT ALLERGY for evaluation and possible skin testing
- Replace Meropenem, Ceftazidime, Cefepime, or Piperacillin-Tazobactam with Ciprofloxacin 400mg IV q8h +/- Aztreonam 2gm IV q8h



## PNEUMONIA



### C. Healthcare associated pneumonia [i.e. from skilled nursing facility, etc]

- Cefepime 2g IV q8h +/- Vancomycin\*\* if h/o MRSA infection/colonization

*Typical Duration: 7 days*

### D. UWMC only: Ventilator-associated Pneumonia (VAP) regardless of hospitalization day

- Treat as **Healthcare associated pneumonia** (section C)

### E. HMC only:

- **Early onset VAP (i.e.  $\leq 4$  days of hospitalization or ventilation) or aspiration:** Ceftriaxone 1g IV q24h OR Ampicillin-sulbactam 3g IV q6h

*Typical Duration: 7 days*

- **Late-onset [ $> 4$  days inpatient],** treat as **Healthcare associated pneumonia** (section C)





## Empiric Abx: *UTI*

### URINARY



**A. Community Acquired Pyelonephritis** (Enteric Gram-negative rods)

*Diagnosis: Clean catch midstream U/A with reflexive gram stain and culture (UACRC). Neutropenic and transplant patients may not mount WBC response; appropriate to cover these patients empirically even without positive U/A if presentation suggests pyelonephritis.*

- Ceftriaxone 1 gm IV q24h
- If patient hemodynamically unstable or history MDRO,  
**CHANGE TO:** Ertapenem 1g q24h

*Typical Duration: 14 days*

## Pitfall:

### SIGNIFICANT PENICILLIN ALLERGY

- Example: anaphylaxis, airway compromise, etc.
- CONSULT ALLERGY for evaluation and possible skin testing
- Replace Meropenem, Ceftazidime, Cefepime, or Piperacillin-Tazobactam with Ciprofloxacin 400mg IV q8h +/- Aztreonam 2gm IV q8h







## Empiric Abx: *UTI*

### Pearls:

- ABU ≠ CAUTI
- Bladder Bundle!


### URINARY

**B. Catheter-associated UTI or Hospital- acquired:**(Resistant Gram-negative rods)

*Diagnosis: In symptomatic pts, obtain specimen from new foley, or from sterilized port on existing foley, not from collection bag or urimeter. Send U/A with reflexive gram stain and culture (UACRC). WBCs and Bacteria on direct stain suggests infection, but colonization also very common.*

- Ceftazidime 2g IV q8h
- If GPC seen on gram stain, add: Vancomycin\*\*
- De-escalate or discontinue coverage if alternate source found for patient symptoms.

*Typical Duration: 7-14 days*



## Empiric Abx: *Belly*

### Pearls:

- No double-anaerobic coverage
- Short course post-appy

### INTRA-ABDOMINAL



#### A. Community-acquired, mild-moderate (Enteric Gram-negative rods, anaerobes)

- **HMC only:** Ertapenem 1g IV q24h
- **UWMC only:** Ceftriaxone 2g IV q24h **PLUS** Metronidazole 500mg PO/IV q8h
- For uncomplicated ***biliary*** infections, anaerobic coverage usually not necessary, use Ceftriaxone alone

*Typical Duration: 4 days following source control*

#### B. Hospital-acquired, severe physiological disturbance, advanced age, immunocompromised

- Vancomycin\*\* **PLUS**
- Piperacillin-tazobactam 4.5gm X 1, then 4 hours later, start 3.375gm IV q8h infused over 4 hours

*Typical Duration: 4-7 days from source control; if source control is not attained, then duration is variable.*

#### C. Intra-abdominal infections:

- ⇒ Double anaerobic coverage is not required (i.e. metronidazole + piperacillin/tazobactam)
- ⇒ Abdominal Transplant patients: Same as above and consult Transplant Infectious Diseases



## Empiric Abx: *Skin*

### Pearls:

- Cellulitis = *Strep* (beta lactam)
- Pus = *S.aureus* (I&D)

## CELLULITIS



*Not-applicable to device-related infections (eg ICD, pacemakers, VADs, etc): Consult Infectious Diseases*

### **A. Non-purulent skin/soft tissue infection:** (*Streptococcus species*)

- Cefazolin 2g IV q8h
- PO option for Strep/MSSA: Cephalexin 500mg QID

### **B. Purulent/abscess forming skin/soft tissue infection:** (*S.aureus*: MSSA or MRSA)

*Diagnosis: I&D abscess; send pus (not wound swab) for gram stain and culture.*

- *Usually abx are unnecessary unless significant surrounding cellulitis or pt clinically unstable*
- Vancomycin\*\*
- De-escalate when culture data available
- PO options for MRSA: Bactrim or Doxycycline (Consult ID)

*Typical Duration: 5-7 days; Consult Infectious Diseases for PO step-down options*



## Empiric Abx: CNS

### Pearls:

- A true emergency
- Do not delay abx for LP or CT

### MENINGITIS



(*S.pneumoniae*, *N.meningitidis* and *H.influenzae*)

Consider Listeria and HSV in patients age > 50, immuno-compromised or alcoholic.)

*Diagnosis: Order antibiotics immediately; Do not wait for results of LP to initiate antimicrobials. LP for opening pressure, gram stain, culture, HSV PCR, cell count, glucose, and protein. Add cryptococcal antigen for HIV patients.*

#### Non-surgical, community-acquired:

- Consider Dexamethasone 0.15mg/kg IV q6 hours for 2-4 days, give 15 minutes prior to abx if possible
- Ceftriaxone 2g IV q 12h **PLUS**
- Vancomycin\*\*
- **ADD** Ampicillin 2g IV q4 hours for Listeria coverage
- **ADD** Acyclovir 10mg/kg IV q8h for HSV coverage when appropriate

*Typical duration: 7-21 days depending on organism*


**Post-surgical meningitis:** (*S.epidermidis*, *S.aureus*, *P.acnes*, gram-negative rods (including *P.aeruginosa*))

- Cefepime 2g IV q8h **PLUS**
- Metronidazole 500mg IV q8h **PLUS**
- Vancomycin\*\*

*Duration: variable*



## **Empiric Abx: *Conclusions***



Paul Pottinger MD

1. Order sets assist with standardization...  
“Easy Button”
2. Get provider buy-in during development
3. Measure use... be willing to modify PRN!

## References



- IDSA Practice Guidelines


[http://www.idsociety.org/IDSA\\_Practice\\_Guidelines/](http://www.idsociety.org/IDSA_Practice_Guidelines/)





# How burdensome are narcotic addictions in your setting?

- A. Rarely see it
- B. Pretty common
- C. Super common!




URL: <http://rwpoll.com>

Code: uwecho

# Have you seen “black tar” heroin in your hospital in the last few years?

- A. Nope
- B. Yep
- C. Not Sure




URL: <http://rwpoll.com>

Code: uwecho

# How many times in the last few years have you discharged an IDU pt with a PICC for OPAT?

- A. Never
- B. 1-5
- C. > 5



URL: <http://rwpoll.com>

Code: uwecho

Thank you!  
See you next week!  
Tuesday March 28, 2017